PCSK9 Inhibition Following Myocardial Infarction: A Right Time to Act

Affiliations

¹ Departments of Medicine and Community Health Sciences, University of Calgary, Calgary, Alberta, Canada; Libin Cardiovascular Institute, Cumming School of Medicine, Calgary, Alberta, Canada. Electronic address: aacleung@ucalgary.ca.
² Libin Cardiovascular Institute, Cumming School of Medicine, Calgary, Alberta, Canada; Department of Cardiac Sciences, Cumming School of Medicine, Calgary, Alberta, Canada.

Editorial

Alexander A Leung et al. Can J Cardiol. 2022 Oct.

. 2022 Oct;38(10):1550-1552.

doi: 10.1016/j.cjca.2022.06.013. Epub 2022 Jun 23.

¹ Departments of Medicine and Community Health Sciences, University of Calgary, Calgary, Alberta, Canada; Libin Cardiovascular Institute, Cumming School of Medicine, Calgary, Alberta, Canada. Electronic address: aacleung@ucalgary.ca.
² Libin Cardiovascular Institute, Cumming School of Medicine, Calgary, Alberta, Canada; Department of Cardiac Sciences, Cumming School of Medicine, Calgary, Alberta, Canada.

No abstract available

Comment on

Alirocumab and Cardiovascular Outcomes in Patients With Previous Myocardial Infarction: Prespecified Subanalysis From ODYSSEY OUTCOMES.
Chiang CE, Schwartz GG, Elbez Y, Szarek M, Bhatt DL, Bittner VA, Diaz R, Erglis A, Goodman SG, Hagström E, Jukema JW, Liberopoulos E, Loy M, Pordy R, White HD, Simon T, Steg PG; ODYSSEY OUTCOMES Investigators. Chiang CE, et al. Can J Cardiol. 2022 Oct;38(10):1542-1549. doi: 10.1016/j.cjca.2022.05.021. Epub 2022 May 27. Can J Cardiol. 2022. PMID: 35644332 Clinical Trial.